Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $5.07M |
| Net Income (Most Recent Fiscal Year) | $-10.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.68 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -280.51% |
| Net Margin (Trailing 12 Months) | -280.53% |
| Return on Equity (Trailing 12 Months) | -2550.30% |
| Return on Assets (Trailing 12 Months) | -320.49% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.76 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 19.46M |
| Free Float | 18.91M |
| Market Capitalization | $7.55M |
| Average Volume (Last 20 Days) | 28.38M |
| Beta (Past 60 Months) | 0.97 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 5.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |